|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0024623,
umls-concept:C0030705,
umls-concept:C0032854,
umls-concept:C0087111,
umls-concept:C0123931,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0348080,
umls-concept:C1561558,
umls-concept:C1704419
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-12-15
|
|
pubmed:abstractText |
Irinotecan (CPT-11) has been tested as a single agent in several studies, and response rates of 18-23% have been reported in first-line gastric cancer therapy. In the present study we report the safety and efficacy results combining CPT-11 with 5-fluorouracil (5-FU) and folinic acid (FA).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-8916
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
379-83
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17168428-Adult,
pubmed-meshheading:17168428-Aged,
pubmed-meshheading:17168428-Antimetabolites, Antineoplastic,
pubmed-meshheading:17168428-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17168428-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17168428-Camptothecin,
pubmed-meshheading:17168428-Disease-Free Survival,
pubmed-meshheading:17168428-Drug Administration Schedule,
pubmed-meshheading:17168428-Female,
pubmed-meshheading:17168428-Fluorouracil,
pubmed-meshheading:17168428-Humans,
pubmed-meshheading:17168428-Kaplan-Meier Estimate,
pubmed-meshheading:17168428-Leucovorin,
pubmed-meshheading:17168428-Male,
pubmed-meshheading:17168428-Middle Aged,
pubmed-meshheading:17168428-Prospective Studies,
pubmed-meshheading:17168428-Stomach Neoplasms,
pubmed-meshheading:17168428-Treatment Outcome
|
|
pubmed:articleTitle |
Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition.
|
|
pubmed:affiliation |
Medical Oncology Unit 2, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
